Related Experiment Video

Updated: Oct 12, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

Angiogenesis inhibition in lung cancer: emerging novel strategies

Chiara Lazzari1, Alessandra Bulotta1, Giuseppe Damiano1

  • 1Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute.

Current Opinion in Oncology
|November 23, 2021
PubMed
Abstract

Insights

Antivascular agents show promise when combined with chemotherapy, immune checkpoint inhibitors, and EGFR-TKIs for advanced non-small cell lung cancer. Further research is needed to identify biomarkers for patient selection and optimize treatment strategies.

Area of Science:

  • Oncology
  • Molecular Medicine
  • Clinical Trial Design

Background:

  • Lung cancer is a leading cause of cancer mortality worldwide.
  • Advances in molecular medicine and immune checkpoint inhibitors have improved patient survival.
  • Antivascular agents targeting VEGF/VEGFR are crucial due to their role in cancer progression.

Purpose of the Study:

  • To review the molecular basis for clinical trials combining antivascular agents with chemotherapy, immune checkpoint inhibitors, and EGFR-TKIs.
  • To explore the efficacy of these combinations in advanced non-small cell lung cancer (NSCLC).

Main Methods:

  • Review of current clinical trial designs.
  • Analysis of molecular rationales for combination therapies.
  • Evaluation of existing clinical data on antivascular agents in NSCLC.

Main Results:

  • Clinical trials indicate synergistic effects between antivascular agents and immune checkpoint inhibitors/EGFR-TKIs.
  • No specific molecular markers have been identified to select patients for these combination therapies.
  • Promising but not definitive conclusions regarding survival benefits.

Conclusions:

  • Combination therapies involving antivascular agents show potential in advanced NSCLC.
  • Further research is essential to identify predictive biomarkers for patient selection.
  • Optimizing treatment strategies requires a deeper understanding of molecular interactions.

More Related Videos

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.1K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
725
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K